{"groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"FG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"FG001","title":"Placebo + Exemestane"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"52"},{"groupId":"FG001","numSubjects":"8"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"47"},{"groupId":"FG001","numSubjects":"7"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Administrative problems"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"New cancer therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"364"},{"groupId":"FG001","numSubjects":"221"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"Treatment completed as per protocol"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"485"},{"groupId":"FG001","numSubjects":"239"}],"type":"STARTED"},{"achievements":[{"comment":"Completed means discontinued the treatment period.","groupId":"FG000","numSubjects":"0"},{"comment":"Completed means discontinued the treatment period.","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"485"},{"groupId":"FG001","numSubjects":"239"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Although 724 patients were randomized, 4 never received any study treatment and thus were excluded form the safety set."}